There is a critical need for the development of non-invasive imaging strategies for tuberous sclerosis (TSC) derived tumor lesions in order to monitor the progression and therapeutic efficacy of this multi-system genetic disease. In this study, we investigated the ability of multiparametric 1H MRI (morphological T2-weighted and functional diffusion-weighted) to meet this need in a preclinical murine model of TSC treated with everolimus. Results indicated that proton MR imaging was able to capture the changes in cellularity and tumor size, post treatment.
This abstract and the presentation materials are available to members only; a login is required.